Journal: bioRxiv

Article Title: Replication-driven HBV cccDNA loss in chimeric mice with humanized livers

doi: 10.1101/2023.12.28.573542

Figure Lengend Snippet: A. Average cccDNA levels were <1 copy/cell in all 380 cccDNA samples isolated from livers of 17 mice under non-partial blocking of de novo infection (two mice: 970 and 819) or blocking of two cccDNA replenishment pathways (the remaining 15 mice). B. Average cccDNA levels were significantly lower than both untreated and treated mice with partial blocking of de novo infection . C1 and C2. Serum HBsAg and HBeAg levels were progressively reduced to undetectable levels among mice with non-partial blocking of de novo infection in mouse 819 or blocking of two pathways in the remaining 7 mice started before peak infection . C3. Kinetic serum anti-HBs antibody level . D1 and D2. Serum HBsAg and HBeAg levels were progressively reduced to undetectable levels upon boosting anti-HBs antibody levels by triweekly administrations of mouse anti-HBs antibody at a dose of 250 μg/injection starting on day 99 pi or later until termination. D3. Kinetic serum anti-HBs antibody level in the same D1/D2 group. E1 and E2. Average rcDNA levels reduced by 2-4 logs among mice through blocking of two pathways (Green) with anti-HBs antibody expressed by HBVZ10 before peak infection (E1) or with administering additional mouse anti-HBs antibody to boost the HBVZ10 expressed anti-HBs antibody level after the peak infection (E2) compared to untreated (Blue). F . Kinetic serum HBsAg levels among 3 mice (805 untreated; 833 HBVZ10 monotherapy, and 838 HBVZ10 combined with 12-week entecavir. G . Average intracellular HBsAg, rcDNA and cccDNA levels reduced by >100-fold in mouse 838 in 80 days compared to mouse 833. HBeAg, hepatitis B e antigen. The difference was considered significant at P<0.05 by Student’s t test. Error bars were plotted with standard deviations.

Article Snippet: Blood was collected tri-weekly for quantification of serum HBV DNA (qPCR see below), HBeAg (CSB-E13557h, CUSABIO), HBsAg (GS HBsAg EIA 32591, Bio-Rad), anti-HBs antibody (MONOLISA Anti-HBs EIA 25200, Bio-Rad) with calibrators (MONOLISA Anti-HBs 20-Calibrator kit 25219, Bio-Rad) and human albumin (Human albumin ELISA kit E-80AL, Immunology Consultants Laboratory) levels by ELISA per instructions.

Techniques: Isolation, Blocking Assay, Infection, Injection

Journal: Virology Journal

Article Title: A study of Epstein-Barr virus infection in the Chinese tree shrew( Tupaia belangeri chinensis )

doi: 10.1186/s12985-017-0859-5

Figure Lengend Snippet: Expression of EBV genes in PBMCs of Ts1–4. In Ts1 and Ts2, only EBNA1 and LMP1 were detected at week 4, respectively. In Ts3, BZLF1 was expressed from weeks 6 to 10, and LMP1 was observed only at week 6.In Ts4, BZLF1 was expressed from weeks 2 to 4, and the expression of LMP1 persisted throughout the observation period with the exception of week 4

Article Snippet: EBV antibodies in tree shrew serum were measured using an enzyme-linked immunosorbent assay (ELISA).The anti-EBV capsid antigen(VCA) IgG,EBV nuclear antigen (EBNA) IgG, and early antigen (EA) IgG were measured with the Epstein-Barr virus VCA IgG ELISA Kit(Abnova,Taiwan, China),a human Epstein-Barr virus nuclear antigen (EBNA1) antibody (IgG) ELISA kit (CUSABIO, Wuhan, China), and a human Epstein-Barr virus early antigen (EBEA) antibody (IgG) ELISA kit (CUSABIO).Tree shrew serum diluted 1:10 with dilution buffer was placed into each plate, and bound antibodies were subsequently detected using rabbit anti-tree shrew IgGsecondary antibody synthesized by Sangon Biotech Co.,Ltd. (Shanghai, China).

Techniques: Expressing

Journal: Virology Journal

Article Title: A study of Epstein-Barr virus infection in the Chinese tree shrew( Tupaia belangeri chinensis )

doi: 10.1186/s12985-017-0859-5

Figure Lengend Snippet: Expression of EBV genes in PBMCs of Ts7–10. In Ts7, the expression of LMP1 persisted throughout the observation period, excluding week 2, BZLF1 appeared at weeks 2 to 4,EA was detected intermittently from weeks 4 to 18, and EBNA1 was observed only at week 18. In Ts8, EBNA1, EBNA2 and LMP1were expressed at week 2. In Ts9, LMP1was detected at weeks 2, 6 and 21, and EA and EBNA1were detected only at weeks 2 and 16, respectively. In Ts10, the expression of BZLF1 persisted throughout the observation period,and LMP1 was detected at week 1

Article Snippet: EBV antibodies in tree shrew serum were measured using an enzyme-linked immunosorbent assay (ELISA).The anti-EBV capsid antigen(VCA) IgG,EBV nuclear antigen (EBNA) IgG, and early antigen (EA) IgG were measured with the Epstein-Barr virus VCA IgG ELISA Kit(Abnova,Taiwan, China),a human Epstein-Barr virus nuclear antigen (EBNA1) antibody (IgG) ELISA kit (CUSABIO, Wuhan, China), and a human Epstein-Barr virus early antigen (EBEA) antibody (IgG) ELISA kit (CUSABIO).Tree shrew serum diluted 1:10 with dilution buffer was placed into each plate, and bound antibodies were subsequently detected using rabbit anti-tree shrew IgGsecondary antibody synthesized by Sangon Biotech Co.,Ltd. (Shanghai, China).

Techniques: Expressing

Journal: Virology Journal

Article Title: A study of Epstein-Barr virus infection in the Chinese tree shrew( Tupaia belangeri chinensis )

doi: 10.1186/s12985-017-0859-5

Figure Lengend Snippet: Levels of EBV antibody in the serum of tree shrews post-infection. The level of VCA IgG increased to varying degrees in all tree shrews in which the EBV copy number increased; EBNA1 IgG increased in only1 tree shrew (Ts7),and EA IgG was not elevated ( a ). The levels of these antibodies were not increased in the EBV-infection-negative tree shrews ( b ) or in any of the 3 tree shrews that served as negative controls (data not shown)

Article Snippet: EBV antibodies in tree shrew serum were measured using an enzyme-linked immunosorbent assay (ELISA).The anti-EBV capsid antigen(VCA) IgG,EBV nuclear antigen (EBNA) IgG, and early antigen (EA) IgG were measured with the Epstein-Barr virus VCA IgG ELISA Kit(Abnova,Taiwan, China),a human Epstein-Barr virus nuclear antigen (EBNA1) antibody (IgG) ELISA kit (CUSABIO, Wuhan, China), and a human Epstein-Barr virus early antigen (EBEA) antibody (IgG) ELISA kit (CUSABIO).Tree shrew serum diluted 1:10 with dilution buffer was placed into each plate, and bound antibodies were subsequently detected using rabbit anti-tree shrew IgGsecondary antibody synthesized by Sangon Biotech Co.,Ltd. (Shanghai, China).

Techniques: Infection

Journal: Virology Journal

Article Title: A study of Epstein-Barr virus infection in the Chinese tree shrew( Tupaia belangeri chinensis )

doi: 10.1186/s12985-017-0859-5

Figure Lengend Snippet: Western blotting for the detection of EBV gene expression in the livers and spleens. EBNA1 was detected in the spleens of Ts2, Ts3, Ts9 and Ts10. No EBNA1 expression was detected in the livers of any of the tree shrews. B95–8 cells and Ts11–13 were used as positive and negative controls, respectively. Ts5 and Ts6 were EBV-infection-negative. No EBNA1expression was detected inTs5, Ts6 or Ts11–13

Article Snippet: EBV antibodies in tree shrew serum were measured using an enzyme-linked immunosorbent assay (ELISA).The anti-EBV capsid antigen(VCA) IgG,EBV nuclear antigen (EBNA) IgG, and early antigen (EA) IgG were measured with the Epstein-Barr virus VCA IgG ELISA Kit(Abnova,Taiwan, China),a human Epstein-Barr virus nuclear antigen (EBNA1) antibody (IgG) ELISA kit (CUSABIO, Wuhan, China), and a human Epstein-Barr virus early antigen (EBEA) antibody (IgG) ELISA kit (CUSABIO).Tree shrew serum diluted 1:10 with dilution buffer was placed into each plate, and bound antibodies were subsequently detected using rabbit anti-tree shrew IgGsecondary antibody synthesized by Sangon Biotech Co.,Ltd. (Shanghai, China).

Techniques: Western Blot, Gene Expression, Expressing, Infection

Journal: OncoTargets and Therapy

Article Title: Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma

doi: 10.2147/ott.s91626

Figure Lengend Snippet: Figure 1 High level of CXCR2 expression shown in cases of high-grade gliomas. Notes: (A) Representative sections for CXCR2 immunohistochemistry (IHC, SP ×400). (a) Normal nontumorous tissue, (b) WHO low-grade glioma, (c) WHO high-grade glioma, (d) negative control for immunostaining. Positive CXCR2 staining = brown; cell nuclei = blue; the arrows show representative results of staining. (B) The population of cells with different levels of CXCR2 expression in glioma and control brain tissue. Overall, the level of CXCR2 expression was significantly higher in WHO III–IV gliomas tissues than in WHO I–II glioma tissues and the control brain tissues according to IHC results. (C) Western blotting of CXCR2 protein level in gliomas and normal tissue. The upper panel is a representative result of Western blotting. CXCR2 protein expression was calculated by normalizing CXCR2 intensity to GAPDH intensity, and data were compared to the normal tissue, represented as 1. Data are expressed as mean ± SD; *P,0.05 versus normal tissue; #P,0.05 between different grades. Abbreviations: CXCR2, C-X-C chemokine receptor 2; WHO, World Health Organization; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SD, standard deviation.

Article Snippet: Western blotting was performed according to standard protocols using the following antibodies: goat anti-glyceraldehyde 3-phosphate dehydrogenase polyclonal antibody (1:800; Santa Cruz Biotechnology Inc., Dallas, TX, USA), anti-human CXCR2 monoclonal antibody (1:500); donkey anti-goat IRDye (1:10,000; Rockland, Limerick, PA, USA), and donkey anti-mouse IRDye (1:10,000; Rockland).

Techniques: Expressing, Immunohistochemistry, Negative Control, Immunostaining, Staining, Control, Western Blot, Standard Deviation

Journal: OncoTargets and Therapy

Article Title: Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma

doi: 10.2147/ott.s91626

Figure Lengend Snippet: Figure 2 CXCR2 inhibitor SB225002 could reduce cell migration. Notes: (A) Representative images for wound healing assay. U251 cells treated with DMSO or with SB225002 (400 nM) at the different time points of 0 hour, 12 hours, 24 hours, 36 hours, and 48 hours, respectively (bar 100 µm). (B) Statistical results of the wound healing assay. Images were analyzed using ImageJ analysis software and data presented as average length of cell-free void ± SD (*P,0.05). Abbreviations: CXCR2, C-X-C chemokine receptor 2; DMSO, dimethyl sulfoxide; SD, standard deviation; h, hour.

Article Snippet: Western blotting was performed according to standard protocols using the following antibodies: goat anti-glyceraldehyde 3-phosphate dehydrogenase polyclonal antibody (1:800; Santa Cruz Biotechnology Inc., Dallas, TX, USA), anti-human CXCR2 monoclonal antibody (1:500); donkey anti-goat IRDye (1:10,000; Rockland, Limerick, PA, USA), and donkey anti-mouse IRDye (1:10,000; Rockland).

Techniques: Migration, Wound Healing Assay, Software, Standard Deviation

Journal: Frontiers in Immunology

Article Title: Serological cross-reactivity between Crimean-Congo haemorrhagic fever virus and Nairobi sheep disease virus glycoprotein C

doi: 10.3389/fimmu.2024.1423474

Figure Lengend Snippet: Orthonairovirus test antigens employed during experiments.

Article Snippet: CCHFV Gc , NP_950235 (IbAr10200, Nigeria) , HEK293 (Human) , The Native Antigen Company, UK #REC31696.

Techniques: Expressing, Plasmid Preparation

Journal: Micromachines

Article Title: Configuration and Design of Electromagnets for Rapid and Precise Manipulation of Magnetic Beads in Biosensing Applications

doi: 10.3390/mi10110784

Figure Lengend Snippet: Dose responses of recombinant human IgM anti-Zika NS1 using a small footprint MMB system (“New MMB”) and a standard MMB system (“MMB”).

Article Snippet: To demonstrate the use of two optimally designed electromagnets in a biosensing application, we measured increasing concentrations of recombinant ZIKV antibodies (Human IgM anti-Zika NS1 monoclonal antibodies, MAB12123, Native Antigen) in an MMB system ( , ).

Techniques: Recombinant